China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective clinical study of Sacituzumab Tirumotecan combined with Pembrolizumab in the treatment of advanced biliary tract cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132859
Registration Time: 2026/09/18
Type: Interventional study
Primary Sponsor: Peking Union Medical College Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337172
Published by HT Digital Content Services with permission from Health Daily Digest....